title: Economic evaluation in chronic pain: a systematic review and de novo flexible economic model.
abstract: There is unmet need in patients suffering from chronic pain, yet innovation may be impeded by the difficulty of justifying economic value in a field beset by data limitations and methodological variability. A systematic review was conducted to identify and summarise the key areas of variability and limitations in modelling approaches in the economic evaluation of treatments for chronic pain. The results of the literature review were then used to support the development of a fully flexible open-source economic model structure, designed to test structural and data assumptions and act as a reference for future modelling practice. The key model design themes identified from the systematic review included: time horizon; titration and stabilisation; number of treatment lines; choice/ordering of treatment; and the impact of parameter uncertainty (given reliance on expert opinion). Exploratory analyses using the model to compare a hypothetical novel therapy versus morphine as first-line treatments showed cost-effectiveness results to be sensitive to structural and data assumptions. Assumptions about the treatment pathway and choice of time horizon were key model drivers. Our results suggest structural model design and data assumptions may have driven previous cost-effectiveness results and ultimately decisions based on economic value. We therefore conclude that it is vital that future economic models in chronic pain are designed to be fully transparent and hope our open-source code is useful in order to aspire to a common approach to modelling pain that includes robust sensitivity analyses to test structural and parameter uncertainty.
authors.affiliation: BresMed Health Solutions, Sheffield, UK.
authors.forename: W
authors.initials: W
authors.lastname: Sullivan
authors.affiliation: MundiPharma International, 194 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0AB, UK.
authors.forename: M
authors.initials: M
authors.lastname: Hirst
authors.affiliation: BresMed Health Solutions, Sheffield, UK.
authors.forename: S
authors.initials: S
authors.lastname: Beard
authors.affiliation: BresMed Health Solutions, Sheffield, UK.
authors.forename: D
authors.initials: D
authors.lastname: Gladwell
authors.affiliation: CEMKA-EVAL, Bourg-la-Reine, France.
authors.forename: F
authors.initials: F
authors.lastname: Fagnani
authors.affiliation: University Castilla-La Mancha, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: López Bastida
authors.affiliation: Swansea University, Swansea, Wales, UK.
authors.forename: C
authors.initials: C
authors.lastname: Phillips
authors.affiliation: MundiPharma International, 194 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0AB, UK. will.dunlop@mundipharma.co.uk.
authors.forename: W C N
authors.initials: WC
authors.lastname: Dunlop
mesh_terms: D000700:Analgesics / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D059350:Chronic Pain / Q000191:economics* / Q000628:therapy; D003362:Cost-Benefit Analysis; D006801:Humans; D017059:Models, Econometric; D009294:Narcotics / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years
chemical_list: D000700:Analgesics; D009294:Narcotics
keywords: Chronic pain; Economic evaluation; Modelling assumptions; Transparency